抗てんかん薬の世界市場レポート 2025年

抗てんかん薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には222億7,000万米ドルに成長し、CAGRは5.5%となります。予測期間の成長は、薬剤耐性てんかん患者の増加、てんかん治療における個別化医療の進展、生物製剤や遺伝子治療の採用拡大、てんかん研究開発への投資拡大、てんかん症例の特定を強化する診断法の改善などが背景にあります。この期間に予想される主要動向には、個別化治療アプローチの進展、薬剤耐性てんかんに対する併用療法の進展、特定の遺伝子変異を標的とした新たな治療法、より安全で有効な抗てんかん薬（AED）の開発への重点化、てんかん発作制御のためのカンナビジオールベースの治療法の使用拡大などがあります。

てんかんの有病率の増加は、今後数年間の抗てんかん薬市場の成長を牽引すると予想されます。てんかんは、脳内の異常な電気的活動によって引き起こされる、誘発性のない発作を繰り返す神経疾患です。事故による頭部外傷の増加により、脳外傷や神経損傷によるてんかん発症リスクが高まっています。抗てんかん薬（AED）は、神経伝達物質やイオンチャネルを調節して脳の活動を安定化させ、神経細胞の過剰な発火を防ぐことによって作用します。これらの薬剤は発作の頻度と重症度の両方を低下させ、てんかん患者の生活の質を向上させています。例えば、てんかん患者を支援する英国の慈善団体「Epilepsy Action」は2022年2月、英国では約63万人がてんかんを患っており、約100人に1人がてんかん患者であると報告しました。このように、てんかんの有病率の増加が抗てんかん薬市場の拡大に寄与しています。

抗てんかん薬市場の主要企業は、急性発作や緊急事態に対してより効果的な治療オプションを提供するため、静脈内投与抗てんかん薬のような先進的製剤の開発に注力しています。静脈内投与製剤は、注射や点滴によって血流に直接投与される即効性のある薬剤であり、特に緊急時や経口薬が適さない、あるいは有効でない場合に、迅速な発作制御を記載しています。例えば、2024年1月、日本の製薬会社であるエーザイは、日本でFycompaの製造販売承認を取得しました。Fycompaはファーストインクラスの高選択的非競合AMPA受容体拮抗薬であり、AMPA受容体のグルタミン酸活性を標的とすることで、てんかん発作につながる神経細胞の興奮亢進を抑制します。点滴静注製剤は、手術中など一時的に経口薬を服用できないてんかん患者の代替薬として開発され、経口投与の中断に伴うてんかん発作のリスクを軽減します。Fycompaは75カ国以上で承認されており、日本では4歳以上の部分てんかんと原発性全般性強直間代発作の併用療法として使用されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の抗てんかん薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の抗てんかん薬市場：成長率分析
• 世界の抗てんかん薬市場の実績：規模と成長、2019～2024年
• 世界の抗てんかん薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の抗てんかん薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗てんかん薬市場：薬剤別、実績と予測、2019～2024年、2024～2029年、2034年
• 第一世代
• 第二世代
• 第三世代
• 世界の抗てんかん薬市場：形態別、実績と予測、2019～2024年、2024～2029年、2034年
• 乾燥
• 液体
• 世界の抗てんかん薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 静脈内
• その他
• 世界の抗てんかん薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• ドラッグストア
• 世界の抗てんかん薬市場、第一世代のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• フェノバルビタール
• フェニトイン
• カルバマゼピン
• バルプロ酸
• プリミドン
• エトスクシミド
• 世界の抗てんかん薬市場、第二世代のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ラモトリギン
• ガバペンチン
• トピラマート
• レベチラセタム
• オキシカルバゼピン
• チアガビン
• フェルバメート
• ゾニサミド
• 世界の抗てんかん薬市場、第三世代のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ラコサミド
• エスリカルバゼピン酢酸塩
• ペランパネル
• ブリバラセタム
• セノバマテ

第7章 地域別・国別分析

• 世界の抗てんかん薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の抗てんかん薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗てんかん薬市場：競合情勢
• 抗てんかん薬市場：企業プロファイル
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

第31章 その他の大手企業と革新的企業

• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Jazz Pharmaceuticals plc
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Amneal Pharmaceuticals Inc.
• Lupin Limited
• Zydus Lifesciences Ltd.
• Alkem Laboratories Ltd.
• Torrent Pharmaceuticals Ltd.
• Supernus Pharmaceuticals Inc.
• SK Biopharmaceuticals Co. Ltd.
• Immedica Pharma AB
• Neurelis Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 抗てんかん薬市場、2029年：新たな機会を提供する国
• 抗てんかん薬市場、2029年：新たな機会を提供するセグメント
• 抗てんかん薬市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Antiepileptic drugs (AEDs) are medications used to control or prevent seizures in people with epilepsy and other neurological disorders. They work by altering neurotransmitter levels or ion channel function in the brain. By stabilizing electrical activity in the brain, AEDs help decrease both the frequency and severity of seizures.

The main categories of antiepileptic drugs include first-generation, second-generation, and third-generation AEDs. First-generation AEDs were the earliest seizure treatments and act by stabilizing brain activity, though they often come with more side effects and complex pharmacokinetics. These drugs come in various forms, including dry and liquid formulations, and can be administered through multiple routes such as oral and intravenous. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

The antiepileptic drugs market research report is one of a series of new reports from The Business Research Company that provides antiepileptic drugs market statistics, including the antiepileptic drugs industry global market size, regional shares, competitors with the antiepileptic drugs market share, detailed antiepileptic drugs market segments, market trends, opportunities, and any further data you may need to thrive in the antiepileptic drugs industry. This antiepileptic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antiepileptic drugs market size has grown strongly in recent years. It will grow from $17.01 billion in 2024 to $18.00 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be linked to the increasing prevalence of epilepsy, heightened awareness of neurological disorders, progress in drug development, government support and funding for epilepsy research, and the expansion of healthcare infrastructure in emerging markets.

The antiepileptic drugs market size is expected to see strong growth in the next few years. It will grow to $22.27 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period is driven by a rising number of patients with drug-resistant epilepsy, advancements in personalized medicine for epilepsy treatment, increased adoption of biologics and gene therapies, growing investments in epilepsy research and development, and improvements in diagnostics that enhance the identification of epilepsy cases. Key trends expected during this period include the advancement of personalized treatment approaches, progress in combination therapies for drug-resistant epilepsy, emerging therapies targeting specific genetic mutations, a stronger focus on developing safer and more effective antiepileptic drugs (AEDs), and expanded use of cannabidiol-based therapies for seizure control.

The rising prevalence of epilepsy is expected to drive the growth of the antiepileptic drugs market in the coming years. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. An increase in head injuries from accidents contributes to a higher risk of developing epilepsy due to brain trauma and neural damage. Antiepileptic drugs (AEDs) work by stabilizing brain activity through modulation of neurotransmitters and ion channels to prevent excessive neuron firing. These drugs reduce both the frequency and severity of seizures, thereby improving the quality of life for people with epilepsy. For example, in February 2022, Epilepsy Action, a UK-based charity that supports individuals with epilepsy, reported that approximately 630,000 people in the UK live with epilepsy-about one in every 100 people-with 80 new cases diagnosed daily. Thus, the growing prevalence of epilepsy is contributing to the expansion of the antiepileptic drug market.

Leading companies in the antiepileptic drugs market are focusing on developing advanced formulations, such as intravenous (IV) antiepileptic drugs, to provide more effective treatment options for acute seizures and emergency situations. IV antiepileptic drugs are fast-acting medications administered directly into the bloodstream via injection or infusion, offering rapid seizure control, especially in emergencies or when oral medications are not suitable or effective. For instance, in January 2024, Eisai Co., Ltd., a Japan-based pharmaceutical firm, received manufacturing and marketing approval for Fycompa in Japan. Fycompa is a first-in-class, highly selective, non-competitive AMPA receptor antagonist that decreases neuronal hyper-excitation linked to seizures by targeting glutamate activity at AMPA receptors. The intravenous formulation was developed as an alternative for epilepsy patients who temporarily cannot take oral medication, such as during surgery, to reduce seizure risks associated with interrupted oral dosing. Fycompa is approved in over 75 countries and is used as an adjunctive treatment for partial-onset seizures and primary generalized tonic-clonic seizures in patients aged 4 years and older in Japan.

In August 2024, AbbVie, a U.S.-based biopharmaceutical company, acquired Cerevel Therapeutics for around $8.7 billion. This acquisition is intended to strengthen AbbVie's neuroscience pipeline and enhance its capacity to develop treatments for neurological and psychiatric disorders. Cerevel Therapeutics is a U.S.-based biotechnology company specializing in the manufacture of antiepileptic drugs.

Major players in the antiepileptic drugs market are Pfizer Inc., Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Supernus Pharmaceuticals Inc., SK Biopharmaceuticals Co. Ltd., Immedica Pharma AB, Neurelis Inc.

North America was the largest region in the antiepileptic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antiepileptic drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antiepileptic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antiepileptic drugs market consists of sales of sodium channel blockers, calcium channel blockers, glutamate inhibitors, and gamma-aminobutyric acid (GABA) enhancers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antiepileptic Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiepileptic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiepileptic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antiepileptic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: First Generation; Second Generation; Third Generation
• 2) By Form: Dry; Liquid
• 3) By Route Of Administration: Oral; Intravenous; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores
• Subsegments:
• 1) By First Generation: Phenobarbital; Phenytoin; Carbamazepine; Valproate; Primidone; Ethosuximide
• 2) By Second Generation: Lamotrigine; Gabapentin; Topiramate; Levetiracetam; Oxcarbazepine; Tiagabine; Felbamate; Zonisamide
• 3) By Third Generation: Lacosamide; Eslicarbazepine Acetate; Perampanel; Brivaracetam; Cenobamate
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Novartis AG; Teva Pharmaceutical Industries Ltd.; UCB S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antiepileptic Drugs Market Characteristics

3. Antiepileptic Drugs Market Trends And Strategies

4. Antiepileptic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Antiepileptic Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antiepileptic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antiepileptic Drugs Market Growth Rate Analysis
• 5.4. Global Antiepileptic Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antiepileptic Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antiepileptic Drugs Total Addressable Market (TAM)

6. Antiepileptic Drugs Market Segmentation

• 6.1. Global Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First Generation
• Second Generation
• Third Generation
• 6.2. Global Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry
• Liquid
• 6.3. Global Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Other Routes Of Administration
• 6.4. Global Antiepileptic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• 6.5. Global Antiepileptic Drugs Market, Sub-Segmentation Of First Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phenobarbital
• Phenytoin
• Carbamazepine
• Valproate
• Primidone
• Ethosuximide
• 6.6. Global Antiepileptic Drugs Market, Sub-Segmentation Of Second Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lamotrigine
• Gabapentin
• Topiramate
• Levetiracetam
• Oxcarbazepine
• Tiagabine
• Felbamate
• Zonisamide
• 6.7. Global Antiepileptic Drugs Market, Sub-Segmentation Of Third Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lacosamide
• Eslicarbazepine Acetate
• Perampanel
• Brivaracetam
• Cenobamate

7. Antiepileptic Drugs Market Regional And Country Analysis

• 7.1. Global Antiepileptic Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antiepileptic Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antiepileptic Drugs Market

• 8.1. Asia-Pacific Antiepileptic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antiepileptic Drugs Market

• 9.1. China Antiepileptic Drugs Market Overview
• 9.2. China Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antiepileptic Drugs Market

• 10.1. India Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antiepileptic Drugs Market

• 11.1. Japan Antiepileptic Drugs Market Overview
• 11.2. Japan Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antiepileptic Drugs Market

• 12.1. Australia Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antiepileptic Drugs Market

• 13.1. Indonesia Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antiepileptic Drugs Market

• 14.1. South Korea Antiepileptic Drugs Market Overview
• 14.2. South Korea Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antiepileptic Drugs Market

• 15.1. Western Europe Antiepileptic Drugs Market Overview
• 15.2. Western Europe Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antiepileptic Drugs Market

• 16.1. UK Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antiepileptic Drugs Market

• 17.1. Germany Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antiepileptic Drugs Market

• 18.1. France Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antiepileptic Drugs Market

• 19.1. Italy Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antiepileptic Drugs Market

• 20.1. Spain Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antiepileptic Drugs Market

• 21.1. Eastern Europe Antiepileptic Drugs Market Overview
• 21.2. Eastern Europe Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antiepileptic Drugs Market

• 22.1. Russia Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antiepileptic Drugs Market

• 23.1. North America Antiepileptic Drugs Market Overview
• 23.2. North America Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antiepileptic Drugs Market

• 24.1. USA Antiepileptic Drugs Market Overview
• 24.2. USA Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antiepileptic Drugs Market

• 25.1. Canada Antiepileptic Drugs Market Overview
• 25.2. Canada Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antiepileptic Drugs Market

• 26.1. South America Antiepileptic Drugs Market Overview
• 26.2. South America Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antiepileptic Drugs Market

• 27.1. Brazil Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antiepileptic Drugs Market

• 28.1. Middle East Antiepileptic Drugs Market Overview
• 28.2. Middle East Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antiepileptic Drugs Market

• 29.1. Africa Antiepileptic Drugs Market Overview
• 29.2. Africa Antiepileptic Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antiepileptic Drugs Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antiepileptic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antiepileptic Drugs Market Competitive Landscape And Company Profiles

• 30.1. Antiepileptic Drugs Market Competitive Landscape
• 30.2. Antiepileptic Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. UCB S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Antiepileptic Drugs Market Other Major And Innovative Companies

• 31.1. Eisai Co. Ltd.
• 31.2. Sun Pharmaceutical Industries Ltd.
• 31.3. Jazz Pharmaceuticals plc
• 31.4. Aurobindo Pharma Ltd.
• 31.5. Dr. Reddy's Laboratories Ltd.
• 31.6. Cipla Ltd.
• 31.7. Amneal Pharmaceuticals Inc.
• 31.8. Lupin Limited
• 31.9. Zydus Lifesciences Ltd.
• 31.10. Alkem Laboratories Ltd.
• 31.11. Torrent Pharmaceuticals Ltd.
• 31.12. Supernus Pharmaceuticals Inc.
• 31.13. SK Biopharmaceuticals Co. Ltd.
• 31.14. Immedica Pharma AB
• 31.15. Neurelis Inc.

32. Global Antiepileptic Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antiepileptic Drugs Market

34. Recent Developments In The Antiepileptic Drugs Market

35. Antiepileptic Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Antiepileptic Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antiepileptic Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antiepileptic Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer